Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-PD-L1 Monoclonal Antibody is a humanized rabbit antibody targeting PD-L1. Anti-PD-L1 Monoclonal Antibody can be used in ELISA,FCM,IF.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 μg | $120 | 12 days | 12 days | |
| 50 μg | $143 | 12 days | 12 days | |
| 100 μg | $201 | 12 days | 12 days |
| Description | Anti-PD-L1 Monoclonal Antibody is a humanized rabbit antibody targeting PD-L1. Anti-PD-L1 Monoclonal Antibody can be used in ELISA,FCM,IF. |
| Synonyms | Programmed cell death 1 ligand 1, B7 homolog 1 |
| Ig Type | Rabbit monoclonal IgG |
| Reactivity | Human |
| Verified Activity | Flow cytometry analysis of PD-L1 overexpressed 293F cells with TMAZ-0055BI, which was counjucated with SA-PE (red). The WT 293F control is black line. |
| Application | |
| Recommended Dose | 0.1-0.2 μg/10E6 cells for FCM; 1 ng/μl for ELISA |
| Antibody Type | Monoclonal |
| Host Species | Rabbit |
| Subcellular Localization | Secreted |
| Construction | This antibody was produced from a rabbit immunized with purified, recombinant human extracellular domain of PD-L1 protein. |
| Purification | Protein A Affinity Purified |
| Appearance | Liquid |
| Formulation | 0.22 μm filtered solution in PBS. |
| Purity | > 95% as determined by SDS-PAGE. |
| Research Background | Plays a critical role in induction and maintenance of immune tolerance to self (PubMed: 11015443, PubMed: 28813410, PubMed: 28813417, PubMed: 31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed: 11015443, PubMed: 28813410, PubMed: 28813417, PubMed: 36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed: 10581077). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed: 32929201)|The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed: 28813410, PubMed: 28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity) |
| Conjucates | Unconjugated |
| Others Formats | Biotin |
| Antibody Types Available | 2 |
| Immunogen | PD-L1 |
| Antigen Species | Human |
| Gene ID | |
| Uniprot ID | |
| Biology Area | Immunology Research |
| Molecular Weight | 150 kDa |
| Stability & Storage | Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. |
| Transport | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.